Nature Communications (Feb 2022)
Small molecule SWELL1 complex induction improves glycemic control and nonalcoholic fatty liver disease in murine Type 2 diabetes
- Susheel K. Gunasekar,
- Litao Xie,
- Ashutosh Kumar,
- Juan Hong,
- Pratik R. Chheda,
- Chen Kang,
- David M. Kern,
- Chau My-Ta,
- Joshua Maurer,
- John Heebink,
- Eva E. Gerber,
- Wojciech J. Grzesik,
- Macaulay Elliot-Hudson,
- Yanhui Zhang,
- Phillip Key,
- Chaitanya A. Kulkarni,
- Joseph W. Beals,
- Gordon I. Smith,
- Isaac Samuel,
- Jessica K. Smith,
- Peter Nau,
- Yumi Imai,
- Ryan D. Sheldon,
- Eric B. Taylor,
- Daniel J. Lerner,
- Andrew W. Norris,
- Samuel Klein,
- Stephen G. Brohawn,
- Robert Kerns,
- Rajan Sah
Affiliations
- Susheel K. Gunasekar
- Department of Internal Medicine, Cardiovascular Division, Washington University School of Medicine
- Litao Xie
- Department of Internal Medicine, Cardiovascular Division, Washington University School of Medicine
- Ashutosh Kumar
- Department of Internal Medicine, Cardiovascular Division, Washington University School of Medicine
- Juan Hong
- Department of Internal Medicine, Cardiovascular Division, Washington University School of Medicine
- Pratik R. Chheda
- Department of Pharmaceutical Sciences and Experimental Therapeutics, University of Iowa, College of Pharmacy
- Chen Kang
- Department of Internal Medicine, Cardiovascular Division, Washington University School of Medicine
- David M. Kern
- Department of Molecular & Cell Biology, University of California Berkeley
- Chau My-Ta
- Feinberg School of Medicine, Northwestern University
- Joshua Maurer
- Department of Internal Medicine, Cardiovascular Division, Washington University School of Medicine
- John Heebink
- Department of Internal Medicine, Cardiovascular Division, Washington University School of Medicine
- Eva E. Gerber
- Department of Molecular & Cell Biology, University of California Berkeley
- Wojciech J. Grzesik
- Stead Family Department of Pediatrics, Endocrinology and Diabetes Division, Fraternal Order of Eagles Diabetes Research Center, University of Iowa
- Macaulay Elliot-Hudson
- Department of Internal Medicine, Cardiovascular Division, University of Iowa
- Yanhui Zhang
- Xiamen Cardiovascular Hospital, Xiamen University
- Phillip Key
- Department of Internal Medicine, Cardiovascular Division, Washington University School of Medicine
- Chaitanya A. Kulkarni
- Department of Pharmaceutical Sciences and Experimental Therapeutics, University of Iowa, College of Pharmacy
- Joseph W. Beals
- Center for Human Nutrition, Washington University School of Medicine
- Gordon I. Smith
- Center for Human Nutrition, Washington University School of Medicine
- Isaac Samuel
- Department of Surgery, University of Iowa, Carver College of Medicine
- Jessica K. Smith
- Department of Surgery, University of Iowa, Carver College of Medicine
- Peter Nau
- Department of Surgery, University of Iowa, Carver College of Medicine
- Yumi Imai
- Department of Internal Medicine, Cardiovascular Division, University of Iowa
- Ryan D. Sheldon
- Department of Biochemistry, University of Iowa
- Eric B. Taylor
- Department of Biochemistry, University of Iowa
- Daniel J. Lerner
- Senseion Therapeutics Inc, BioGenerator Labs
- Andrew W. Norris
- Stead Family Department of Pediatrics, Endocrinology and Diabetes Division, Fraternal Order of Eagles Diabetes Research Center, University of Iowa
- Samuel Klein
- Center for Human Nutrition, Washington University School of Medicine
- Stephen G. Brohawn
- Department of Molecular & Cell Biology, University of California Berkeley
- Robert Kerns
- Department of Pharmaceutical Sciences and Experimental Therapeutics, University of Iowa, College of Pharmacy
- Rajan Sah
- Department of Internal Medicine, Cardiovascular Division, Washington University School of Medicine
- DOI
- https://doi.org/10.1038/s41467-022-28435-0
- Journal volume & issue
-
Vol. 13,
no. 1
pp. 1 – 25
Abstract
Type 2 diabetes is associated with insulin resistance, impaired insulin secretion and liver steatosis. Here the authors report a proof-of-concept study for small molecule SWELL1 modulators as a therapeutic approach to treat diabetes and associated liver steatosis by enhancing systemic insulin-sensitivity and insulin secretion in mice.
